What is LOPJLB’s current signal on SVRA?

LOPJLB’s latest quantitative signal on Savara Inc. (SVRA) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is SVRA in?

Savara Inc. (SVRA) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Savara Inc. (SVRA) do?

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main …

Savara Inc. (SVRA)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$4.78-1.24%Close

SELLRECOVERY · day 3

Company news

businesswire.com · 2d ago

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

defenseworld.net · 45d ago

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

defenseworld.net · 49d ago

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

defenseworld.net · 51d ago

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

businesswire.com · 51d ago

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

businesswire.com · 55d ago

Savara Announces New Employment Inducement Grant

businesswire.com · 64d ago

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

seekingalpha.com · 71d ago

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

businesswire.com · 77d ago

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

zacks.com · 85d ago

Here's Why You Should Add Savara Stock to Your Portfolio Now

Market news & ticker search · RSS for SVRA

FAQ

What is LOPJLB’s current signal on SVRA?: LOPJLB’s latest quantitative signal on Savara Inc. (SVRA) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is SVRA in?: Savara Inc. (SVRA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Savara Inc. (SVRA) do?: Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main …

Savara Inc. (SVRA)

Key stats

Industry peers

Prediction markets

Company news

FAQ